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ORIGINAL RESEARCH
Clinical Implications of Estimated 
Glomerular Filtration Rate Dip Following 
Sodium- Glucose Cotransporter- 2 Inhibitor 
Initiation on Cardiovascular and Kidney 
Outcomes
Yan Xie , MPH; Benjamin Bowe , MPH; Andrew K. Gibson , MPH; Janet B. McGill, MD; Geetha Maddukuri, MD; 
Ziyad Al- Aly , MD
BACKGROUND: The frequency of the initial short- term decline in estimated glomerular filtration rate (eGFR), eGFR dip, following 
initiation of sodium- glucose cotransporter- 2 inhibitors (SGLT2i) and its clinical implications in real- world practice are not clear.
METHODS AND RESULTS: We built a cohort of 36 638 new users of SGLT2i and 209 025 new users of other antihyperglycemics. 
Inverse probability weighting was used to estimate the excess rate of eGFR dip, risk of the composite cardiovascular outcome 
of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or all- cause mortality, and risk of the compos-
ite kidney outcome of eGFR decline >50%, end- stage kidney disease, or all- cause mortality. In the first 6 months of therapy, 
compared with other antihyperglycemics, excess rates of eGFR dip >10% and eGFR dip >30% were 9.86 (95% CI: 8.83– 11.00) 
and 1.15 (0.70– 1.62) per 100 SGLT2i users, respectively. In mediation analyses that accounted for eGFR dipping, SGLT2i use 
was associated with reduced risk of cardiovascular and kidney outcomes (hazard ratio, 0.92 [0.84– 0.99] and 0.78 [0.71– 0.87], 
respectively); the magnitude of the association reduced by eGFR dipping was small for both outcomes. SGLT2i was associ-
ated with reduced risk of both outcomes in those with higher than average probability of eGFR dip >10% or 30%. Compared 
with discontinuation, continued use of SGLT2i at 6 months was associated with reduced risk of cardiovascular and kidney 
outcomes in those with no eGFR dip or eGFR dip ≤10%, in those with eGFR dip >10%, and in those with eGFR dip >30%.
CONCLUSIONS: The salutary association of SGLT2i with cardiovascular and kidney outcomes was maintained regardless of 
eGFR dipping; concerns about eGFR dipping should not preclude use, and occurrence of eGFR dip after SGLT2i initiation 
may not warrant discontinuation.
Key Words: cardiovascular outcomes ■ diabetes mellitus ■ estimated glomerular filtration rate ■ kidney ■ kidney function  
■ kidney outcomes ■ sodium- glucose cotransporter- 2 inhibitors
Several randomized clinical trials provided evidence that sodium- glucose cotransporter- 2 inhibitors (SGLT2i) reduce the risk of major cardiovascular 
and kidney outcomes in people with type 2 diabetes 
mellitus.1– 7 Evidence from recent trials suggests that 
the salutary properties of SGLT2i may even extend to 
people without diabetes mellitus.8– 10 However, in sev-
eral randomized trials, SGLT2i use was associated with 
an initial estimated glomerular filtration rate (eGFR) de-
cline, eGFR dip, within a few weeks and up to 6 months 
following initiation of therapy.11 The eGFR dip is gener-
ally followed by recovery and stabilization during the 
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subsequent months; in the long- term, SGLT2i use was 
associated with relative eGFR preservation compared 
with placebo.11
However, the frequency and extent of eGFR dip 
in SGLT2i users relative to other antihyperglycemics, 
whether eGFR dipping erodes SGLT2i effectiveness 
on cardiovascular and kidney outcomes, and whether 
eGFR dip is associated with increased risk of discontin-
uation of SGLT2i in real- world practice are not known. 
Furthermore, whether continued SGLT2i use (versus 
discontinuation) following an intervening SGLT2i dip 
is associated with reduced risk of cardiovascular and 
kidney outcomes is unknown. Addressing this knowl-
edge gap will illuminate our understanding of the clini-
cal ramifications of the eGFR dip in SGLT2i users.
Herein, we leveraged the breadth and depth of 
the US Department of Veterans Affairs (VA) electronic 
healthcare databases to build a cohort of 36 638 inci-
dent users of SGLT2i, and 209 025 incident users of 
other antihyperglycemics, and aimed to characterize 
the rates of eGFR dipping in each antihyperglycemic 
group, identify characteristics associated with eGFR 
dipping in SGLT2i users, examine whether and to what 
extent the effectiveness of SGLT2i on cardiovascular 
and kidney outcomes was abrogated by an intervening 
eGFR dip, and finally evaluate the risk of major cardio-
vascular outcomes and kidney outcomes associated 
with SGLT2i continuation versus discontinuation ac-
cording to eGFR dipping category.
METHODS
Because of the sensitive nature of the data used in this 
study, the data sets could only be accessed after ob-
taining approval from the VA.
Cohort Design
Participants who received antihyperglycemic medica-
tion from the VA Health Care System between October 
1, 2015, and July 31, 2019, were selected (n=1 293 984). 
Participants were separated first into an SGLT2i group, 
which included patients who received an SGLT2i pre-
scription between October 1, 2016, and July 31, 2019 
(n=59  133). The other antihyperglycemic group was 
then selected from participants who did not receive 
SGLT2i prescription between October 1, 2016, and July 
31, 2019. The other antihyperglycemic group included 
patients who either added on or switched from their 
existing non- SGLT2i antihyperglycemic medication to 
a non- SGLT2i antihyperglycemic prescription between 
October 1, 2016, and July 31, 2019 (n=423 193), where 
the first date of meeting this criterion was considered 
time of treatment initiation. In each group, partici-
pants without a history of SGLT2i exposure within the 
1 year before treatment initiation were selected (SGLT2i 
CLINICAL PERSPECTIVE
What Is New?
• In the first 6 months of treatment, estimated glo-
merular filtration rate (eGFR) dipping was more 
common among sodium- glucose cotrans-
porter- 2 inhibitor (SGLT2i) users than other 
antihyperglycemics; however, most eGFR dips 
were <30%.
• eGFR dipping did not abrogate the beneficial 
association between SGLT2i and cardiovascu-
lar and kidney outcomes.
• Continued use of SGLT2i (versus discontinua-
tion) was associated with reduced risk of car-
diovascular and kidney outcomes regardless of 
degree of eGFR dipping.
What Are the Clinical Implications?
• Real- world effectiveness of SGLT2i on cardio-
vascular and kidney outcomes was maintained 
regardless of eGFR dipping.
• Concern about dipping should not preclude 
initiation of SGLT2i, and occurrence of an eGFR 
dip following SGLT2i initiation should not, on its 
own, motivate SGLT2i discontinuation.
• As a means of achieving longer- term reduction 
in risk of cardiovascular and kidney outcomes, 
practitioners may consider continuation of 
treatment with SGLT2i regardless of eGFR 
dipping.
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group, n=55 466; and other antihyperglycemic group, 
n=420 625). We further excluded participants with his-
tory of type 1 diabetes mellitus, those with end- stage 
kidney disease, or those who were enrolled in the 
healthcare system for <1  year at treatment initiation 
(SGLT2i group, n=51 816; and other antihyperglycemic 
group, n=387 467). Within participants who remained in 
the cohort, 46 122 in the SGLT2i group and 312 794 in 
the other antihyperglycemic group had measurements 
of glycated hemoglobin (HbA1c), low- density lipopro-
teins, blood pressure, height, weight, and had eGFR 
measurement ≥30 mL/min per 1.73 m2 within the 1 year 
before treatment initiation. To evaluate the change in 
eGFR within the first 6 months (180 days) after treatment 
initiation, we removed participants who had no eGFR 
measurement or who experienced the composite cardi-
ovascular or kidney outcome in this time period (SGLT2i 
group, n=36 638; and other antihyperglycemic group, 
n=209 025). Participants were followed until the occur-
rence of an outcome or administrative end of follow-
 up (January 31, 2020). Informed consent was waived 
for this study. The cohort flowchart is presented in 
Figure S1, and study timeline is presented in Figure S2.
Data Sources
Data from the VA Corporate Data Warehouse (CDW) 
were used in this study.12– 26 CDW Outpatient and 
Inpatient Encounters domains included International 
Classification of Diseases, Tenth Revision (ICD- 10), di-
agnosis codes, ICD- 10 procedure codes, and Current 
Procedural Terminology codes.27 Medication pre-
scriptions were obtained from the CDW Outpatient 
Pharmacy domain. Laboratory measurements from the 
CDW Laboratory Results domain were also collected 
and used.28 The CDW Vital Signs domain provided vital 
measurements, and the CDW Patient domain and VA 
Vital Status provided demographic information.29
Exposure and Outcomes
Prescriptions of SGLT2i or other antihyperglycemic 
medications were identified from outpatient pharmacy 
records. The distribution of antihyperglycemic medica-
tions at treatment initiation is presented in Table S1.15,30
Differences in rates of eGFR dip >10% and >30% 
between the SGLT2i and other antihyperglycemic 
groups were examined. eGFR dip was evaluated on 
the basis of the difference between baseline eGFR, 
defined as the average eGFR within 1  year before 
treatment initiation, and the lowest eGFR value mea-
sured within 6  months after the treatment initiation. 
The difference was transformed into percentage 
change compared with baseline eGFR. The CKD 
Epidemiology Collaboration creatinine equation was 
used to compute eGFR based on serum creatinine, 
age, race, and sex.31
SGLT2i discontinuation was defined as a >90- day 
gap between the last supply date of a prescription and 
the next prescription, where the date of the last supply 
was within 6 months after treatment initiation. The asso-
ciations between discontinuation of SGLT2i and the car-
diovascular and kidney outcomes were examined. The 
composite cardiovascular outcome was defined as non-
fatal myocardial infarction, nonfatal stroke, hospitalization 
for heart failure, or all- cause mortality. The composite 
kidney outcome was defined as eGFR decline >50% 
from treatment initiation, end- stage kidney disease, or 
all- cause mortality. Time of end- stage kidney disease 
was identified by first occurrence of eGFR <15 mL/min 
per 1.73 m2, long- term dialysis, or kidney transplant.
Covariates
Baseline Covariates
Covariate selection was informed by prior knowl-
edge.15,17,18,20,22,24,32 Covariates that may influence 
antihyperglycemic prescription included age, race 
(White, Black, and other, where other race included 
non- White and non- Black participants), sex, HbA1c, 
eGFR, systolic blood pressure, diastolic blood pres-
sure, low- density lipoproteins, body mass index (com-
puted from height and weight), smoking status (never, 
former, or current), type of hospital system where the 
antihyperglycemic was prescribed (outpatient clinic or 
healthcare system), and the calendar year of enroll-
ment. eGFR was the average eGFR within 1 year be-
fore treatment initiation. Clinical comorbidities, such as 
congestive heart failure, cardiovascular diseases, can-
cer, alcoholism, hypoglycemia, diabetic ketoacidosis, 
acute kidney injury, bladder and urinary tract infections, 
venous thromboembolism, pancreatitis, bone fracture, 
and albuminuria, were also included.33 Acute kidney 
injury was defined as an increased serum creatinine 
of 0.3 mg/dL or 50% within 30 days, and albuminuria 
status was categorized into no albuminuria (≤30 mg/g), 
microalbuminuria (>30– ≤300  mg/g), and macroal-
buminuria (>300  mg/g). History use of glucagon- like 
peptide 1 agonists, dipeptidyl peptidase- 4 inhibitors, 
sulfonylureas, thiazolidinediones, metformin, insulin, α- 
glucosidase inhibitors, meglitinides, amylin analogues, 
statins, angiotensin- converting enzyme inhibitors or 
angiotensin receptor blockers, β- blockers, loop diuret-
ics, nonloop diuretics, and calcium channel blockers 
was also used as covariates.33 Covariates were ascer-
tained within the 1 year before the treatment initiation.
Characteristics Within 6 Months After 
Treatment Initiation
To examine characteristics that may be associated with 
SGLT2i discontinuation, we additionally evaluated the 
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diabetic ketoacidosis, amputation, bladder and urinary 
tract infections, venous thromboembolism, pancreati-
tis, bone fracture, hospitalizations that were not related 
to adverse events, and HbA1c change (categorized 
as increase or lack of increase in HbA1c) within the 
6 months after treatment initiation.
Statistical Analysis
Characteristics of the cohort and by treatment group 
and eGFR dip categories are presented as mean and 
SD, or number and percentage, as appropriate. A sche-
matic of the analytic approach is presented in Figure S3.
Rates of eGFR Dip and Predictors of the Dip
Differences in rate of eGFR dips, including dip >10% 
and dip >30%, between the SGLT2i group and other 
antihyperglycemic group were examined by weighted 
generalized estimating equations for logistic regres-
sion. To balance potential confounders between 
treatments, inverse probability of treatment weight-
ing method was applied.34 Probability of receiving 
the assigned treatment at treatment initiation was 
estimated from logistic regression based on covari-
ates ascertained at treatment initiation. The inverse 
probability of treatment weighting was then con-
structed as the inverse probability stabilized by the 
prevalence of treatments at time of treatment initia-
tion. The inverse probability of treatment weighting 
was then truncated at the 0.1 and 99.9 percentiles 
to further stabilize the weighting.35 Absolute rate per 
100 patients in each group and the excess rates as-
sociated with SGLT2i were estimated on the basis 
of the predicted probability. We additionally evalu-
ated the excess rates in subgroups based on race, 
eGFR category, and albuminuria category, and in 
those with congestive heart failure and those using 
angiotensin- converting enzyme inhibitors/angioten-
sin receptor blockers, loop diuretics, and nonloop 
diuretics. We also investigated the characteristics 
that may be associated with eGFR dip >10% and dip 
>30% in SGLT2i users using logistic regressions.
eGFR Dip and the Effectiveness of SGLT2i on 
Cardiovascular and Kidney Outcomes
We evaluated the mediation effect of eGFR dip on the 
associations between SGLT2i and composite cardio-
vascular and kidney outcomes through inverse odds 
ratio (OR) weighting for causal mediation analysis.36 In 
mediation analyses, we estimated the direct effect inde-
pendent of eGFR dip >10% and, in separate analyses, 
eGFR dip >30%. The total effect of SGLT2i, accounted 
for eGFR dipping as a mediator was estimated from a 
Cox model weighted by inverse probability of treatment 
weighting. Direct effect of SGLT2i was estimated from 
a similarly weighted Cox model where the model was 
additionally weighted for the inverse OR of having the 
mediator in the SGLT2i group. The magnitude of effect 
abrogated by the mediator was then computed from 
the difference between hazard ratios (HRs) for the di-
rect effect independent of eGFR dip and the HRs for 
the total effect. Event rate differences between direct 
and total effect were estimated on the basis of survival 
probability, where the difference represented the differ-
ence in the rate of the outcome between the SGLT2i 
and other antihyperglycemic groups that was mediated 
by differences in the rate of eGFR dipping.
To assess whether the salutary association of 
SGLT2i on composite cardiovascular and kidney out-
comes was abrogated in SGLT2i users with a high 
probability of experiencing an eGFR dip associated 
with SGLT2i, we estimated the association between 
SGLT2i and risk of the composite cardiovascular out-
come and the composite kidney outcome in SGLT2i 
users with a higher or lower than average predicted 
probability of having an eGFR dip >10%, and sepa-
rately eGFR dip >30%, associated with SGLT2i (ie, the 
excess probability of having an eGFR dip associated 
with SGLT2i compared with other antihyperglycemics 
after consideration of baseline characteristics). We first 
estimated the predicted baseline probability of eGFR 
dip associated with covariates at treatment initiation 
within the other antihyperglycemic group using logis-
tic regression. Using results from this model, we then 
computed the baseline probability of dip in the SGLT2i 
group. Then, the probability of eGFR dip associated 
with SGLT2i (PSGLT2i dip), conditional on the baseline 
probability of dipping, was estimated within the SGLT2i 
group. The SGLT2i users were then separated into 
high and low risk of experiencing an eGFR dip asso-
ciated with SGLT2i, based on PSGLT2i dip being above 
or below the mean predicted probability. The associa-
tion between SGLT2i and the risk of outcomes in users 
with predicted probability of SGLT2i- related eGFR dip 
higher or lower than the average probability was exam-
ined after adjusting for covariates at treatment initiation.
Association Between SGLT2i 
Discontinuation and Risk of Outcomes
We then examined the association between SGLT2i 
discontinuation with characteristics occurring between 
treatment initiation and 6 months after treatment initia-
tion, which included eGFR dip, adverse events, hospi-
talization, and HbA1c change. Logistic regression was 
used and adjusted for probability of discontinuation. 
The probability was estimated from a logistic regres-
sion where discontinuation was predicted by the set of 
baseline covariates.
Associations between SGLT2i discontinuation and 
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examined from Cox survival models weighted by the 
inverse probability of discontinuation weight, where the 
weight was constructed on the basis of the probability 
of discontinuation and updated by additionally includ-
ing factors that occur between treatment initiation and 
6  months after treatment initiation. The effects were 
estimated in all cohorts, and within those with no eGFR 
dip or dip ≤10%, eGFR dip >10%, and eGFR dip >30%, 
separately. The composite cardiovascular and kidney 
event rates in 1 year by discontinuation and continua-
tion of SGLT2i and their differences were calculated on 
the basis of the estimated survival probabilities.
Evaluation of Potential Biases
Balance of covariates between the SGLT2i and other 
antihyperglycemic group, and between SGLT2i con-
tinuation and discontinuation, was examined through 
propensity score distribution and standardized differ-
ence of covariates. To test the robustness of our analy-
ses, we tested a negative outcome control as a means 
to detect the presence of spurious associations.37 
Traffic- related injury was used as the negative out-
come control as there is neither biologic plausibility nor 
a priori evidence suggesting the presence of a relation-
ship with either SGLT2i use or SGLT2i discontinuation.
Other Statistical Considerations
The 95% CIs for rate difference were generated on the 
basis of 1000 times bootstrapping. A 95% CI for ratio 
measure that does not cross 1 or for rate that does 
not cross 0 was considered statistically significant. 
All analyses were done using SAS Enterprise Guide 
version 7.1 (SAS Institute, Cary, NC). The study was 
approved by the Institutional Review Board of the VA 
Saint Louis Health Care System, Saint Louis, MO.
RESULTS
There were 36  638 individuals in the SGLT2i group 
and 209  025 individuals in the other antihyperglyce-
mic group, corresponding to 447  399 person- years. 
Among incident SGLT2i users, there were 20  458 
(55.84%) with no eGFR dip, 16 180 (44.16%) with eGFR 
dip >10%, and 2326 (6.35%) with eGFR dip >30% 
within the first 6 months of SGLT2i initiation. Baseline 
demographic and health characteristics in these 
groups are provided in Table 1.
Rates of eGFR Dip in the First 6 Months 
Among SGLT2i Users and Users of Other 
Antihyperglycemics
Unadjusted rates of eGFR dip >10% within the first 
6 months were 44.16 (95% CI: 43.66– 44.67) and 30.37 
(30.17– 30.56) per 100 people in the SGLT2i and other 
antihyperglycemic group, respectively (Table  S2). In 
adjusted analyses, compared with other antihypergly-
cemics, excess rate of eGFR dip >10% was 9.86 (8.83– 
11.0) per 100 users of SGLT2i (Figure  S4). Results 
showed consistently higher rates of eGFR dip >10% 
in the SGLT2i group than other antihyperglycemics in 
prespecified subgroups (Table S3).
Unadjusted rates of eGFR dip >30% within the 
first 6 months were 6.35 (95% CI: 6.10– 6.60) and 4.12 
(4.03– 4.20) in the SGLT2i and other antihyperglyce-
mic groups, respectively. In adjusted analyses, the 
excess rate of eGFR dip >30% attributable to SGLT2i 
was small (1.15 [0.70– 1.62] per 100 users of SGLT2i) 
(Figure 1), and it was nonsignificant in several prespec-
ified subgroups (Table S3).
Characteristics Associated With eGFR 
Dip Among SGLT2i Users
Black race, lower eGFR category, congestive heart 
failure, history of acute kidney injury, microalbuminuria, 
macroalbuminuria, angiotensin- converting enzyme in-
hibitor/angiotensin receptor blocker use, loop diuretic 
use, and nonloop diuretic use were associated with 
higher risk of eGFR dip >10% and eGFR dip >30% 
(Table 2).
eGFR Dip and the Effectiveness of SGLT2i 
on Cardiovascular and Kidney Outcomes
To estimate whether and to what extent the protec-
tive association between SGLT2i and cardiovascular 
and kidney outcomes may be abrogated by an in-
tervening eGFR dip (conditioned on the probability 
of eGFR dip), we first developed mediation analyses 
where eGFR dip was considered a mediator. In anal-
yses for the composite cardiovascular outcome, the 
total effect size that accounted for eGFR dipping as 
a mediator was 0.92 (95% CI: 0.84– 0.99); estimates 
of the association independent of eGFR dip >10% 
and eGFR dip >30% yielded an HR of 0.88 (0.81– 
0.92) and 0.90 (0.82– 0.98), respectively, suggesting 
that the magnitude of risk reduction abrogated by 
eGFR dipping was 3.78% (2.22%– 5.44%) and 1.18% 
(0.62%– 2.22%) for eGFR dip >10% and eGFR dip 
>30%, respectively (Figure 2 and Table S4).
In analyses, for the composite kidney outcome, the 
total effect size that accounted for eGFR dipping as a 
mediator was 0.78 (95% CI: 0.71– 0.87); estimates of 
the association independent of eGFR dip >10% and 
eGFR dip >30% yielded an HR of 0.73 (0.65– 0.82) 
and 0.76 (0.68– 1.86), suggesting that the magnitude of 
risk reduction abrogated by eGFR dipping was 4.76% 
(3.17%– 6.85%) and 1.66% (0.87%– 3.01%) for eGFR 
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No eGFR Dip 
or Dip ≤10% 
(n=20 458; 
55.84%)
eGFR Dip >10% 
(n=16 180; 44.16%)
eGFR Dip >30% 
(n=2326; 6.35%)
Age, mean (SD), y 65.73 (10.55) 65.30 (9.11) 64.71 (9.36) 66.06 (8.71) 66.26 (8.12)
Race, n (%)
White 145 909 (69.80) 27 169 (74.16) 15 479 (75.66) 11 690 (72.25) 1623 (69.78)
Black 39 357 (18.83) 5297 (14.46) 2685 (13.12) 2612 (16.14) 413 (17.76)
Other* 23 759 (11.37) 4172 (11.39) 2294 (11.21) 1878 (11.61) 290 (12.47)
Sex, n (%)
Men 197 727 (94.59) 35 016 (95.57) 19 529 (95.46) 15 487 (95.72) 2217 (95.31)
Women 11 298 (5.41) 1622 (4.43) 929 (4.54) 693 (4.28) 109 (4.69)
eGFR, mean (SD), mL/min per 1.73 m2 76.05 (20.45) 78.84 (17.51) 80.77 (17.79) 75.72 (16.73) 73.38 (16.62)
eGFR category, n (%)
eGFR ≥90 mL/min per 1.73 m2 57 407 (27.46) 10 120 (27.62) 7006 (34.25) 3114 (19.25) 342 (14.70)
90 mL/min per 1.73 m2>eGFR≥60 mL/min 
per 1.73 m2
97 261 (46.53) 19 882 (54.27) 10 455 (51.10) 9427 (58.26) 1261 (54.21)
60 mL/min per 1.73 m2> eGFR≥45 mL/min 
per 1.73 m2
36 044 (17.24) 5881 (16.05) 2697 (13.18) 3184 (19.68) 627 (26.96)
45 mL/min per 1.73 m2>eGFR ≥30 mL/min 
per 1.73 m2
18 313 (8.76) 755 (2.06) 300 (1.47) 455 (2.81) 96 (4.13)
HbA1c, mean (SD), % 8.75 (1.93) 8.71 (1.37) 8.71 (1.39) 8.70 (1.34) 8.76 (1.40)
Body mass index, mean (SD), kg/m2 32.87 (6.53) 34.25 (6.41) 34.17 (6.41) 34.35 (6.39) 34.69 (6.58)
Low- density lipoprotein, mean (SD), mg/dL 89.97 (36.93) 80.95 (33.77) 82.10 (34.00) 79.50 (33.43) 79.05 (35.05)
Systolic blood pressure, mean (SD), mm Hg 132.92 (17.06) 132.35 (16.04) 131.97 (15.67) 132.82 (16.49) 133.71 (17.31)
Diastolic blood pressure, mean (SD), mm Hg 76.32 (10.43) 75.03 (9.81) 75.32 (9.73) 74.65 (9.89) 74.15 (9.89)
Congestive heart failure, n (%) 12 896 (6.17) 3416 (9.32) 1496 (7.31) 1920 (11.87) 417 (17.93)
Alcoholism, n (%) 12 148 (5.81) 1479 (4.04) 817 (3.99) 662 (4.09) 111 (4.77)
Bone fracture, n (%) 2656 (1.27) 423 (1.115) 208 (1.02) 215 (1.33) 51 (2.19)
Cancer, n (%) 42 861 (20.51) 7599 (20.74) 3986 (19.48) 3613 (22.33) 573 (24.63)
Cardiovascular disease, n (%) 51 284 (24.53) 14 635 (39.94) 7671 (37.50) 6964 (43.04) 1117 (48.02)
Diabetic ketoacidosis, n (%) 840 (0.40) 70 (0.19) 39 (0.19) 31 (0.19) 5 (0.21)
Hypoglycemia, n (%) 3855 (1.84) 1224 (3.34) 586 (2.86) 638 (3.94) 124 (5.33)
Pancreatitis, n (%) 2474 (1.18) 446 (1.22) 210 (1.03) 236 (1.46) 45 (1.93)
Bladder and urinary tract infections, n (%) 7328 (3.51) 746 (2.04) 377 (1.84) 369 (2.28) 76 (3.27)
Venous thromboembolism, n (%) 1359 (0.65) 214 (0.58) 113 (0.55) 101 (0.62) 14 (0.60)
Acute kidney injury, n (%) 18 821 (9.00) 3101 (8.46) 1388 (6.78) 1713 (10.59) 406 (17.45)
Albuminuria, n (%)
None (≤30 mg/g) 88 410 (42.30) 14 414 (39.34) 8871 (43.36) 5543 (34.26) 595 (25.58)
Microalbuminuria (>30– ≤300 mg/g) 102 139 (48.86) 18 608 (50.79) 10 053 (49.14) 8555 (52.87) 1306 (56.15)
Macroalbuminuria (>300 mg/g) 18 476 (8.84) 3616 (9.87) 1534 (7.50) 2082 (12.87) 425 (18.27)
Metformin, n (%) 109 958 (52.61) 29 760 (81.23) 16 616 (81.22) 13 144 (81.24) 1876 (80.65)
Insulin, n (%) 56 150 (26.86) 20 705 (56.51) 10 892 (53.24) 9813 (60.65) 1543 (66.34)
Sulfonylureas, n (%) 61 094 (29.23) 17 734 (48.40) 9999 (48.88) 7735 (47.81) 1048 (45.06)
DPP4, n (%) 9683 (4.63) 9362 (25.56) 5298 (25.90) 4064 (25.12) 509 (21.88)
GLP1, n (%) 2921 (1.40) 4798 (13.10) 2616 (12.79) 2182 (13.49) 333 (14.32)
Thiazolidinediones, n (%) 3918 (1.87) 3081 (8.41) 1666 (8.14) 1415 (8.75) 211 (9.07)
Total No. of diabetes mellitus medications 
used, mean (SD)
1.18 (0.81) 2.35 (0.93) 2.32 (0.94) 2.39 (0.92) 2.39 (0.92)
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To determine whether the association between 
SGLT2i and cardiovascular and kidney outcomes re-
mained significant in people with higher than average 
probability of experiencing an eGFR dip following 
SGLT2i initiation, we tested the association in groups 
based on the predicted probability of eGFR dipping 
associated with SGLT2i exposure (categorized as 
above and below average; where average probability 
for eGFR dip >10% and eGFR dip >30% was 11.64% 
and 1.92%, respectively). The results suggest that the 
association between SGLT2i and cardiovascular and 
kidney outcomes remained significant even in those 
with higher than average probability of eGFR dip 
>10% and eGFR dip >30% (Figure 3 and Table S5). 
The association was also significant in those with 
below average probability of eGFR dipping (Figure 3 
and Table S5).
eGFR Dip and Characteristics Associated 
With SGLT2i Discontinuation at 6 Months
Rates of SGLT2i discontinuation at 6  months were 
21.83% in the overall SGLT2i group, and 22.10%, 20.12%, 
and 29.58% in those with no eGFR dip, 10%<eGFR 
dip≤30%, and eGFR dip >30%, respectively.
In analyses that balanced demographic and health 
characteristics at baseline, we considered a battery of 
putative characteristics that may be associated with 
SGLT2i discontinuation and occurred following SGLT2i 
initiation and before 6 months. eGFR dip >30%, but 
not eGFR dip of 10% to 30%, was associated with 
increased risk of SGLT2i discontinuation (Table  S6). 
The analyses also identified adverse events, including 
amputation, pancreatitis, bladder and urinary tract in-
fections, hospitalization, and HbA1c increase, as char-
acteristics associated with increased odds of SGLT2i 
discontinuation (Table S6).
Risk of Cardiovascular and Kidney 
Outcomes Associated With SGLT2i 
Continuation or Discontinuation at 
6 Months by eGFR Dipping Category
We examined the risk of a composite cardiovascular 
outcome (of nonfatal myocardial infarction, nonfatal 
stroke, hospitalization for heart failure, or all- cause 
mortality) associated with continued use of SGLT2i 
versus discontinuation at 6  months in each eGFR 
dipping category. The results suggested that com-








No eGFR Dip 
or Dip ≤10% 
(n=20 458; 
55.84%)
eGFR Dip >10% 
(n=16 180; 44.16%)
eGFR Dip >30% 
(n=2326; 6.35%)
Calcium channel blockers, n (%) 56 994 (27.27) 11 133 (30.39) 5716 (27.94) 5417 (33.48) 877 (37.70)
β- Blockers, n (%) 79 898 (38.22) 18 992 (51.84) 9859 (48.19) 9133 (56.45) 1478 (63.54)
Diuretics, n (%)
Loop diuretics 25 216 (12.06) 5970 (16.29) 2690 (13.15) 3280 (20.27) 662 (28.46)
Nonloop diuretics 51 521 (24.65) 9771 (26.67) 5030 (24.59) 4741 (29.30) 759 (32.63)
Statins, n (%) 144 393 (69.08) 31 222 (85.22) 17 179 (83.97) 14 043 (86.79) 2066 (88.82)
Type of hospital system, n (%)
Outpatient clinic 126 384 (60.46) 19 387 (52.92) 10 959 (53.57) 8428 (52.09) 1174 (50.47)
Healthcare system 82 641 (39.54) 17 251 (47.08) 9499 (46.43) 7752 (47.91) 1152 (49.53)
Year of treatment initial, n (%)
2016 18 247 (8.73) 746 (2.04) 412 (2.01) 334 (2.06) 35 (1.50)
2017 76 758 (36.72) 6747 (18.42) 3868 (18.91) 2879 (17.79) 388 (16.68)
2018 72 696 (34.78) 13 478 (36.79) 7608 (37.19) 5870 (36.28) 812 (34.91)
2019 41 324 (19.77) 15 667 (42.76) 8570 (41.89) 7097 (43.86) 1091 (46.90)
Smoking status, n (%)
Never 95 093 (45.49) 17 062 (46.57) 9555 (46.71) 7507 (46.40) 1093 (46.99)
Former 65 260 (31.22) 12 092 (33.00) 6685 (32.68) 5407 (33.42) 753 (32.37)
Current 48 672 (23.29) 7484 (20.43) 4218 (20.62) 3266 (20.19) 480 (20.64)
Data are presented as mean (SD) or number (percentage). ACEI indicates angiotensin- converting enzyme inhibitor; ARB, angiotensin receptor blocker; DPP4, 
dipeptidyl peptidase- 4 inhibitor; eGFR, estimated glomerular filtration rate; GLP1, glucagon- like peptide- 1 agonist; HbA1c, glycated hemoglobin; and SGLT2i, 
sodium- glucose co- transporter- 2 inhibitor.
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was associated with reduced risk of cardiovascular 
outcomes in nondippers, in those with eGFR dip 
>10%, and in those with eGFR dip >30% (Figure 4 
and Table S7).
We then examined the risk of a composite kidney 
outcome (of eGFR decline >50%, end- stage kidney 
disease, or all- cause mortality) associated with con-
tinued use of SGLT2i versus discontinuation in each 
eGFR dipping category. The results suggested that 
compared with discontinuation, continued use of 
SGLT2i was associated with reduced risk of compos-
ite kidney outcome in nondippers, in those with eGFR 
dip >10%, and in those with eGFR dip >30% (Figure 4 
and Table S7).
Evaluation of Potential Biases
Propensity score distribution and standardized differ-
ence of covariates across treatment groups and across 
discontinuation status are presented in Figures  S5 
through S7. Plots suggested good overlap of the pro-
pensity score across groups, and all covariates are 
well balanced after weighting. A negative outcome 
control was applied following the same analytic algo-
rithm to examine if the associations observed were at-
tributable to possible spurious biases. Traffic- related 
injury, which should not causally exhibit an associa-
tion with SGLT2i use or SGLT2i continuation, was used 
as negative outcome control. There was no significant 
association between SGLT2i and traffic- related injury 
(OR: 0.96 [95% CI: 0.83– 1.10]) or between SGLT2i con-
tinuation and traffic- related injury (HR: 0.93 [95% CI: 
0.63– 1.36]).
DISCUSSION
In this cohort study of 36 638 incident users of SGLT2i 
and 209 025 incident users of other antihyperglycemics, 
our results suggest that eGFR dip was more frequent 
following initiation of SGLT2i than other antihyperglyce-
mics; however, most eGFR dips were <30%. Mediation 
analyses suggested that eGFR dip following initiation 
of SGLT2i does not substantially abrogate the effec-
tiveness of SGLT2i on cardiovascular and kidney out-
comes. Analyses based on the predicted probability of 
eGFR dipping suggested that even in those with higher 
than average probability of eGFR dipping, SGLT2i use 
was still associated with reduced risk of cardiovascu-
lar and kidney outcomes. Although eGFR dip <30% 
was not associated with SGLT2i discontinuation, eGFR 
dip >30% (a relatively infrequent event) was associated 
Figure 1. Adjusted rates of estimated glomerular filtration rate (eGFR) dip in the first 6 months 
among users of sodium- glucose cotransporter- 2 inhibitor (SGLT2i) and other antihyperglycemics.
Adjusted rates of eGFR dip >10% to 20%, >20% to 30%, and >30% in the SGLT2i group (blue) and the 





 http://ahajournals.org by on Septem
ber 13, 2021
J Am Heart Assoc. 2021;10:e020237. DOI: 10.1161/JAHA.120.020237 9
Xie et al eGFR Dip in SGLT2i
with SGLT2i discontinuation. Compared with those 
who discontinue SGLT2i in the first 6 months of ther-
apy, and after accounting for characteristics that were 
associated with discontinuation, SGLT2i continuation 
was associated with reduced risk of cardiovascular 
and kidney outcomes regardless of eGFR dipping.
Our findings suggest that eGFR dipping is not 
uncommon following SGLT2i initiation in real- world 
setting (rate of eGFR dip >10% was 9.86 [95% CI: 
8.83– 11.0] per 100 users of SGLT2i); however, most 
eGFR dips were <30% as rate of eGFR dip >30% was 
relatively infrequent (1.15 [0.70– 1.62] per 100 users of 
SGLT2i). In the EMPA- REG OUTCOME (Empagliflozin 
Cardiovascular Outcome Event Trial in Type 2 Diabetes 
Mellitus Patients), 28.3% of empagliflozin users ex-
perienced an eGFR dip >10% and 1.4% experi-
enced an eGFR dip of >30%.38 In the CREDENCE 
(Evaluation of the Effects of Canagliflozin on Renal and 
Cardiovascular Outcomes in Participants With Diabetic 
Nephropathy) trial, rates of eGFR dip >10% and >30% 
were 21% and 4%, respectively.4 The relatively higher 
rates of eGFR dipping in these randomized trials com-
pared with the real- world data provided in this report 
are likely a reflection of the higher underlying risk of 
eGFR dip among trial participants.
Our mediation analyses, which considered the con-
tribution of an intervening eGFR dip following initiation of 
SGLT2i, suggested that dipping does not abrogate the 
salutary association between SGLT2i and cardiovascular 
and kidney outcomes. Furthermore, our analyses sug-
gest that even in those with higher than average proba-
bility of eGFR dipping, the association between SGLT2i 
and cardiovascular and kidney outcomes remained 
protective. Last, the results suggested that even after 
accounting for characteristics associated with discon-
tinuation at 6 months, continuation of SGLT2i use was 
associated with reduced risk of the composite cardio-
vascular and kidney outcomes. Taken together, the 
constellation of findings suggests that, although eGFR 
dipping may be more common in SGLT2i users (than 
Table 2. Characteristics Associated With eGFR Dip Among SGLT2i Users
Characteristics
Adjusted Odds Ratio (95% CI)
eGFR Dip >10% eGFR Dip >30%
Age 1.00 (0.99– 1.00) 0.99 (0.98– 0.99)
Race (reference=White)
Black 1.40 (1.31– 1.49) 1.29 (1.15– 1.46)
Other* 1.02 (0.95– 1.09) 1.01 (0.88– 1.15)
Women 1.09 (0.98– 1.21) 1.20 (0.97– 1.48)
eGFR category (reference=eGFR ≥90 mL/min per 1.73 m2)
90 mL/min per 1.73 m2>eGFR≥60 mL/min per 1.73 m2 2.02 (1.91– 2.14) 1.90 (1.66– 2.16)
60 mL/min per 1.73 m2>eGFR≥45 mL/min per 1.73 m2 2.44 (2.26– 2.63) 2.89 (2.48– 3.38)
45 mL/min per 1.73 m2>eGFR≥30 mL/min per 1.73 m2 2.90 (2.46– 3.41) 3.01 (2.31– 3.92)
Albuminuria (reference=no albuminuria)
Microalbuminuria (>30– ≤300 mg/g) 1.22 (1.16– 1.27) 1.46 (1.32– 1.61)
Macroalbuminuria (>300 mg/g) 1.63 (1.50– 1.76) 1.90 (1.65– 2.18)
HbA1c 1.00 (0.99– 1.02) 1.03 (1.00– 1.06)
Low- density lipoprotein 1.00 (1.00– 1.00) 1.00 (1.00– 1.00)
Systolic blood pressure 1.00 (1.00– 1.00) 1.00 (1.00– 1.01)
Diastolic blood pressure 1.00 (0.99– 1.00) 0.99 (0.99– 1.00)
Congestive heart failure 1.19 (1.09– 1.29) 1.30 (1.13– 1.49)
Cardiovascular disease 1.04 (0.99– 1.09) 1.06 (0.97– 1.17)
Acute kidney injury 1.12 (1.03– 1.21) 1.45 (1.28– 1.65)
ACEI/ARB 1.10 (1.04– 1.15) 1.22 (1.10– 1.35)
Diuretics (reference=no diuretic use)
Loop diuretics 1.38 (1.29– 1.48) 1.70 (1.50– 1.93)
Nonloop diuretics 1.29 (1.23– 1.36) 1.59 (1.44– 1.77)
Statins 0.98 (0.92– 1.04) 0.99 (0.86– 1.14)
Models additionally adjusted for sex, body mass index, smoking status, type of hospital system, cancer, alcoholism, hypoglycemia, diabetic ketoacidosis, 
bladder and urinary tract infections, venous thromboembolism, pancreatitis, bone fracture, and history use of glucagon- like peptide- 1 agonist, dipeptidyl 
peptidase- 4 inhibitor, sulfonylureas, thiazolidinediones, metformin, insulin, α- glucosidase inhibitors, meglitinides, amylin analogues, β- blockers, and calcium 
channel blockers. ACEI indicates angiotensin- converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; 
HbA1c, glycated hemoglobin; and SGLT2i, sodium- glucose co- transporter- 2 inhibitor.




 http://ahajournals.org by on Septem
ber 13, 2021
J Am Heart Assoc. 2021;10:e020237. DOI: 10.1161/JAHA.120.020237 10
Xie et al eGFR Dip in SGLT2i
other antihyperglycemics), concern about dipping should 
not preclude initiation of SGLT2i. Another key message 
from our analyses is that regardless of eGFR dip in the 
first 6  months following initiation of SGLT2i, continued 
use of SGLT2i may be more beneficial to long- term kid-
ney and cardiovascular outcomes than discontinuation; 
Figure 2. Risk of composite cardiovascular and kidney outcomes associated with sodium- glucose cotransporter- 2 
inhibitor (SGLT2i) (vs other antihyperglycemics) based on mediation analyses.
Mediation analyses based on inverse odds ratio weighting and adjusted for covariates measured at treatment initiation. The total effect 
accounted for estimated glomerular filtration rate (eGFR) dipping as the mediator. The estimates independent of eGFR dip represent the effect 
that was not mediated by eGFR dip. The magnitude of effect abrogated by the mediator was estimated from the difference between hazard 
ratios (HRs) independent of eGFR dip and the HRs for the total effect and presented as a percentage. CVD indicates cardiovascular disease.
*Composite CVD outcome of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or all- cause mortality. 
†Composite kidney outcome of eGFR decline >50%, end- stage kidney disease, or all- cause mortality.
Hazard ratio
Magnitude of effect 






























Figure 3. Risk of composite cardiovascular and kidney outcomes associated with sodium- glucose cotransporter- 2 inhibitor 
(SGLT2i) (vs other antihyperglycemics) in groups based on predicted probability of SGLT2i- related estimated glomerular 
filtration rate (eGFR) dip.
High and low probability of eGFR dip, categorized as above and below average predicted probability of eGFR dip associated with 
SGLT2i. Average predicted probability was 11.64% and 1.92% for eGFR dip >10% and eGFR dip >30%, respectively. Model was 
adjusted for covariates measured at treatment initiation. CVD indicates cardiovascular disease; and HR, hazard ratio.
*Composite CVD outcome of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or all- cause mortality. 
†Composite kidney outcome of eGFR decline >50%, end- stage kidney disease, or all- cause mortality.
Hazard ratio
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practitioners may consider continuation of treatment with 
SGLT2i as a means of achieving longer- term reduction in 
risk of cardiovascular and kidney outcomes.
Our analyses of factors associated with eGFR 
discontinuation suggest that the occurrence of ad-
verse events, hospitalization, or increase in HbA1c (a 
marker of worsening glycemic control) was associated 
with discontinuation of SGLT2i. Furthermore, eGFR 
dip >30% was also associated with increased risk of 
discontinuation. These results may be useful in guid-
ing efforts to examine whether some of these patient 
groups may benefit from resumption of treatment with 
SGLT2i.39
The mechanism underpinning the eGFR dip in 
SGLT2i is not entirely clear.11,40,41 It has been sug-
gested that this initial dip is reminiscent of the mild 
decline in eGFR observed in some patients following 
initiation of angiotensin- converting enzyme inhibitor/
angiotensin receptor blocker, which is generally at-
tributed to postglomerular (efferent) vasodilatation 
and reduced hyperfiltration.11,42 Several other hypoth-
eses are being tested, including potential contribution 
of enhanced proximal tubular natriuresis leading to 
activation of tubuloglomerular feedback and resultant 
preglomerular (afferent) vasoconstriction.11,40,41,43 The 
constellation of evidence from randomized controlled 
trials and real- world studies suggests that the initial 
eGFR dip is likely a functional (and reversible) dip that 
does not reflect kidney injury and is then followed by 
eGFR stabilization, and ultimately reduced risk of ad-
verse cardiovascular and kidney outcomes.11,17,18,41 
The results of our analyses are congruent with this 
understanding and support the assessment that 
eGFR dip does not substantially erode the effective-
ness of SGLT2i on cardiovascular and kidney out-
comes, and that even in those with eGFR dip >30%, 
continued therapy with SGLT2i was more beneficial 
for longer- term cardiovascular and kidney outcomes 
than discontinued therapy.
This study has several limitations. We used obser-
vational real- world data from the VA to build our co-
hort, which was mostly composed of older, White, and 
male participants, which may limit the generalizabil-
ity of study findings. Although our analytic approach 
evaluated SGLT2i versus other active non- SGLT2i 
antihyperglycemics, considered known confounders, 
and applied inverse probability weighting to generate 
balance in characteristics between the 2 treatment 
groups, we cannot completely rule out the possibility 
of residual confounding. Although we used validated 
definitions to define covariates, exposures, and out-
comes based on diagnostic codes, procedure codes, 
laboratory data, and pharmacy data, we cannot com-
pletely rule out misclassification. Because empagli-
flozin represents >97% of SGLT2i use at the VA, we 
restricted our analyses to empagliflozin, and we did not 
examine within SGLT2i class differences. We defined 
discontinuation based on pharmacy records; hence, 
the exact discontinuation date may not be accurate. 
Although we estimated the probability of discontinua-
tion by leveraging a priori knowledge through inclusion 
of a comprehensive set of covariates, the direct clini-
cal reason (or indication) of medication discontinuation 
may not have been accounted for in our analyses. The 
Figure 4. Risk of composite cardiovascular and kidney outcomes associated with sodium- glucose cotransporter- 2 inhibitor 
(SGLT2i) continuation vs discontinuation by estimated glomerular filtration rate (eGFR) dipping category.
Model adjusted for both covariates measured at treatment initiation and characteristics evaluated within 6 months after treatment 
initiation. CVD indicates cardiovascular disease; and HR, hazard ratio.
*Composite CVD outcome of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or all- cause mortality. 
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estimation of absolute rate difference was based on 
the baseline risk in our cohort, which may vary in other 
populations with different baseline risks.
The study has several strengths. We used large- 
scale real- world data from the VA, which operates 
the largest integrated healthcare system in the United 
States; VA data are captured during routine clinical 
care, which might more closely recapitulate real- 
world experiences.17,18,44 The selection of antihyper-
glycemics or discontinuation in VA was less likely 
driven by financial considerations. We developed our 
research aims, study design, and execution to spe-
cifically address the knowledge gap of real- world 
clinical implications of eGFR dip and the effect of 
discontinuation versus continuation on clinical out-
comes, which may not be addressed in randomized 
controlled trials.45 In addition to reporting relative risk, 
we reported absolute risk differences that may be 
meaningful in informing clinical decision making.45 We 
used a new user design (new SGLT2i users) with ac-
tive comparator (new other antihyperglycemic users) 
and applied advanced statistical methods, including 
inverse probability of treatment weighting, and addi-
tionally accounted for events in the first 6 months of 
therapy that may be associated with discontinuation 
to evaluate the risk of outcomes in users who con-
tinue versus discontinue SGLT2i. We additionally eval-
uated both risk of major cardiovascular and kidney 
outcomes to address questions relevant to the clinical 
community. Finally, the successful testing of negative 
controls, generally used to detect spurious associa-
tions, lessens concern that the observed associations 
of interest may be attributable to biases.
In sum, our results suggest that eGFR dipping is 
not uncommon following initiation of SGLT2i; how-
ever, most eGFR dips were <30%. The salutary 
association between SGLT2i and cardiovascular 
and kidney outcomes was not abrogated by eGFR 
dipping. Continuation of SGLT2i (versus discontin-
uation) was associated with reduced risk of car-
diovascular and kidney outcomes in those with no 
eGFR dip, and in those with eGFR dip >10% and 
eGFR dip >30%.
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Medication class Medication names Distribution at 
treatment initiation 
SGLT2i Empagliflozin 36638 (14.91%) 
Biguanide Metformin 58873 (23.96%) 
Insulin Insulin 33563 (13.66%) 
Sulfonylureas Glyburide, Glipizide, 
Glimepiride 
56568 (23.03%) 
DPP4 Alogliptin, Sitagliptin, 
Saxagliptin, Linagliptin 
31744 (12.92%) 




Thiazolidinediones Pioglitazone, Rosiglitazone 10428 (4.24%) 
Alpha-glucosidase 
inhibitors 
Miglitol, Acarbose 1902 (0.77%) 
Meglitinides Nateglinide, Repaglinide 283 (0.12%) 
Amylin analogues Pramlintide 18 (0.01%) 
SGLT2i=sodium-glucose co-transporter-2 inhibitor. DPP4=dipeptidyl peptidase-4 
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Table S2. Unadjusted rate of eGFR dip>10% and dip> 30% in SGLT2i and the other antihyperglycemics 
group. 
 Unadjusted rate of eGFR dip>10% per 
100 patients  
(95% Confidence interval) 
Unadjusted rate of eGFR dip>30% per 
100 patients 
(95% Confidence interval) 

























































































































































SGLT2i=sodium-glucose co-transporter-2 inhibitor. eGFR=estimated glomerular filtration rate. HbA1c=glycated 
hemoglobin. ACE/ARB=angiotensin converting enzyme inhibitors/angiotensin-receptor blockers.  
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Table S3. Adjusted rates of eGFR dip>10% in SGLT2i and the other antihyperglycemics group 




Adjusted rate per 100 patients 
(95% confidence interval) 








Overall cohort 1.54 
 (1.47, 1.61) 
40.65 
 (40.11, 41.19) 
30.79 
 (30.59, 30.98) 
9.86 
 (8.83, 11.00) 
Race-White 1.48 
 (1.41, 1.57) 
39.10 
 (38.49, 39.72) 
30.19 
 (29.96, 30.43) 
8.91 
 (7.77, 10.01) 
Race-Black 1.93 
 (1.72, 2.18) 
47.22 
 (45.7, 48.74) 
31.62 
 (31.17, 32.08) 
15.60 
 (12.81, 18.65) 
Race-Other 1.45 
 (1.26, 1.66) 
41.65 
 (40.05, 43.27) 
33.05 
 (32.46, 33.65) 
8.40 




 (1.16, 1.41) 
27.30 
 (26.36, 28.26) 
22.71 
 (22.37, 23.05) 
4.59 




 (1.53, 1.72) 
43.00 
 (42.26, 43.74) 
31.76 
 (31.47, 32.05) 
11.28 




 (1.47, 1.81) 
47.14 
 (45.79, 48.50) 
35.3 
 (34.81, 35.80) 
11.84 




 (1.13, 1.95) 
52.03 
 (48.26, 55.79) 
42.21 
 (41.5, 42.93) 
9.78 




 (1.33, 1.54) 
33.96 
 (33.14, 34.80) 
26.43 
 (26.14, 26.72) 
7.53 
 (5.99, 9.20) 
Microalbuminuria 
(>30- ≤300 mg/g) 
1.63 
 (1.53, 1.74) 
43.49 
 (42.73, 44.26) 
32.05 
 (31.76, 32.33) 
11.44 




 (1.29, 1.7) 
53.60 
 (51.85, 55.34) 
43.83 
 (43.11, 44.54) 
9.77 




 (1.22, 1.62) 
52.02 
 (50.27, 53.77) 
43.55 
 (42.7, 44.4) 
8.47 




 (1.11, 1.54) 
51.81 
 (49.9, 53.72) 
45.20 
 (44.49, 45.9) 
6.61 
 (2.96, 11.04) 
ACE/ARB * 1.57 
 (1.50, 1.66) 
42.95 
 (42.31, 43.6) 
32.35 
 (32.09, 32.62) 
10.60 
 (9.27, 11.90) 
Loop diuretics * 1.45 
 (1.30, 1.61) 
50.53 
 (49.20, 51.86) 
41.38 
 (40.78, 41.99) 
9.15 




 (1.53, 1.81) 
44.40 
 (43.35, 45.46) 
32.44 
 (32.04, 32.84) 
11.96 
 (9.76, 13.87) 
SGLT2i=sodium-glucose co-transporter-2 inhibitor. eGFR=estimated glomerular filtration rate. HbA1c=glycated 
hemoglobin. ACE/ARB=angiotensin converting enzyme inhibitors/angiotensin-receptor blockers. Model 
adjusted for covariates measured at treatment initiation. 
* Within patients with history of the disease or used the medication 
 
Adjusted rates of eGFR dip>30% in SGLT2i and the other antihyperglycemics group 




Adjusted rate per 100 patients  
(95% confidence interval) 








Overall cohort 1.28 
 (1.17, 1.41) 
5.40 
 (5.16, 5.66) 
4.26 
 (4.17, 4.34) 
1.15 
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Race-White 1.22 
 (1.09, 1.37) 
4.93 
 (4.66, 5.21) 
4.07 
 (3.97, 4.17) 
0.86 
 (0.39, 1.36) 
Race-Black 1.95 
 (1.55, 2.47) 
8.10 
 (7.31, 8.97) 
4.32 
 (4.12, 4.52) 
3.80 
 (2.03, 5.63) 
Race-Other 0.97 
 (0.77, 1.21) 
5.17 
 (4.49, 5.95) 
5.34 
 (5.07, 5.64) 
-0.17 




 (0.92, 1.51) 
2.91 
 (2.57, 3.29) 
2.48 
 (2.36, 2.61) 
0.43 




 (1.20, 1.53) 
5.03 
 (4.71, 5.36) 
3.76 
 (3.64, 3.88) 
1.27 




 (1.18, 1.64) 
7.97 
 (7.26, 8.73) 
5.85 
 (5.62, 6.1) 
2.11 




 (0.84, 2.01) 
11.94 
 (9.7, 14.61) 
9.46 
 (9.04, 9.89) 
2.48 




 (0.99, 1.43) 
3.15 
 (2.85, 3.47) 
2.65 
 (2.55, 2.76) 
0.49 
 (-0.02, 1.10) 
Microalbuminuria 
(>30- ≤300 mg/g) 
1.35 
 (1.19, 1.53) 
6.24 
 (5.88, 6.62) 
4.71 
 (4.58, 4.84) 
1.53 




 (0.92, 1.39) 
10.18 
 (9.17, 11.29) 
9.1 
 (8.7, 9.53) 
1.08 




 (1.04, 1.63) 
12.29 
 (11.19, 13.49) 
9.71 
 (9.21, 10.23) 
2.58 




 (0.77, 1.29) 
11.68 
 (10.51, 12.96) 
11.72 
 (11.27, 12.18) 
-0.04 
 (-2.36, 3.09) 
ACE/ARB * 1.29 
 (1.16, 1.43) 
6.22 
 (5.92, 6.54) 
4.90 
 (4.78, 5.03) 
1.32 
 (0.69, 1.97) 
Loop diuretics * 1.18 
 (0.99, 1.40) 
10.19 
 (9.41, 11.02) 
8.79 
 (8.44, 9.14) 
1.40 




 (1.25, 1.71) 
6.31 
 (5.81, 6.84) 
4.41 
 (4.24, 4.59) 
1.90 
 (1.13, 2.77) 
 
SGLT2i=sodium-glucose co-transporter-2 inhibitor. eGFR=estimated glomerular filtration rate. HbA1c=glycated 
hemoglobin. ACE/ARB=angiotensin converting enzyme inhibitors/angiotensin-receptor blockers. Model 
adjusted for covariates measured at treatment initiation. 
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Table S4. Risk of composite cardiovascular and kidney outcomes associated with SGLT2i (vs. other 
antihyperglycemics) based on mediation analyses. 














































Mediation analyses based on inverse odds ratio-weighting for causal mediation analysis and adjusted for 
covariates measured at treatment initiation. 
The total effect accounted for eGFR dipping as the mediator. The hazard ratio independent of mediator 
represent the effect which was not mediated by eGFR dip. The magnitude of effect abrogated by the mediator 
was estimated from the difference between hazard ratios independent of eGFR dip and the hazard ratios for 
the total effect. 
* Composite cardiovascular outcome was defined as non-fatal myocardial infarction, non-fatal stroke, 
hospitalization for heart failure or all-cause mortality  
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Table S5. Risk of composite cardiovascular and kidney outcomes associated with SGLT2i by predicted 
probability of SGLT2i related eGFR dip. 
Outcomes Group based 
on probability 
of eGFR dip   
Adjusted hazard ratio 
(95% confidence interval) 
Event rate difference per 
100 patient-years 























































High and low probability of eGFR dip categorized based on probability of eGFR dipping associated with 
SGLT2i above or below the average, which are 11.64% for dip>10% and 1.92% for dip>30%. Model adjusted 
for covariates measured at treatment initiation. 
* Composite cardiovascular outcome was defined as non-fatal myocardial infarction, non-fatal stroke, 
hospitalization for heart failure or all-cause mortality  
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Table S6. Characteristics associated with discontinuation among SGLT2i users. 
  Prevalence (%) Discontinuation rate 
per 100 patients * 
(95% confidence 
interval) 
Adjusted odds ratio 
(95% confidence 
interval) 
eGFR dip category 
No dip or dip≤10% (reference) 20454 (55.84) 22.10 
(21.53, 22.67) 
1.00 





























Bladder & urinary tract 
infections 









Hospitalization not related to 
adverse events 










Characteristics were evaluated within 6 months after treatment initiation. Model adjusted for covariates 
measured at treatment initiation. 
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Table S7. Risk of composite cardiovascular and kidney outcomes associated with SGLT2i continuation 
vs. discontinuation by eGFR dipping category. 






rate per 100 
patient-years 







rate per 100 
patient-years  






















































































Model adjusted for both covariates measured at treatment initiation and characteristics evaluated within 6 
months after treatment initiation. 
* Composite cardiovascular outcome was defined as non-fatal myocardial infarction, non-fatal stroke, 
hospitalization for heart failure or all-cause mortality  
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Observed rates of eGFR dip >10 to 20%, >20 to 30% and >30% in the SGLT2i group (blue) and the other 
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Figure S6a. Propensity score distribution before weighting for those who continued and those who 
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Figure S6b. Propensity score distribution after weighting for those who continued and those who 
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Figure S7a. Standardized difference of covariates between the treatment groups (SGLT2i and other 
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Figure S7b. Standardized difference of covariates between those who continued and those who 
discontinued SGLT2i treatment in the first 6 months in the original cohort and the weighted cohort.  
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